These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

932 related items for PubMed ID: 17327610

  • 1. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib.
    Heng DY, Kollmannsberger C.
    Recent Results Cancer Res; 2010 Mar 01; 184():71-82. PubMed ID: 20072832
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR, Leggas M.
    Clin Ther; 2007 Jul 01; 29(7):1338-53. PubMed ID: 17825686
    [Abstract] [Full Text] [Related]

  • 4. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
    Mena AC, Pulido EG, Guillén-Ponce C.
    Anticancer Drugs; 2010 Jan 01; 21 Suppl 1():S3-11. PubMed ID: 20110785
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib in solid tumors.
    Gan HK, Seruga B, Knox JJ.
    Expert Opin Investig Drugs; 2009 Jun 01; 18(6):821-34. PubMed ID: 19453268
    [Abstract] [Full Text] [Related]

  • 6. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
    Cabebe E, Wakelee H.
    Drugs Today (Barc); 2006 Jun 01; 42(6):387-98. PubMed ID: 16845442
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L.
    Expert Opin Pharmacother; 2012 Jun 01; 13(9):1323-36. PubMed ID: 22607009
    [Abstract] [Full Text] [Related]

  • 8. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS, Syrigos KN.
    BioDrugs; 2009 Jun 01; 23(6):377-89. PubMed ID: 19894779
    [Abstract] [Full Text] [Related]

  • 9. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A.
    Oncologist; 2007 Feb 01; 12(2):191-200. PubMed ID: 17296815
    [Abstract] [Full Text] [Related]

  • 10. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 01; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 11. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    Polyzos A.
    J Steroid Biochem Mol Biol; 2008 Feb 01; 108(3-5):261-6. PubMed ID: 17945482
    [Abstract] [Full Text] [Related]

  • 12. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.
    Mol Cancer Ther; 2006 Jul 01; 5(7):1774-82. PubMed ID: 16891463
    [Abstract] [Full Text] [Related]

  • 13. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.
    George S.
    Curr Oncol Rep; 2007 Jul 01; 9(4):323-7. PubMed ID: 17588358
    [Abstract] [Full Text] [Related]

  • 14. Molecular basis for sunitinib efficacy and future clinical development.
    Faivre S, Demetri G, Sargent W, Raymond E.
    Nat Rev Drug Discov; 2007 Sep 01; 6(9):734-45. PubMed ID: 17690708
    [Abstract] [Full Text] [Related]

  • 15. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM, Szczylik C, Rini B.
    Expert Rev Anticancer Ther; 2014 Sep 01; 14(9):983-99. PubMed ID: 25066545
    [Abstract] [Full Text] [Related]

  • 16. The potential role of sunitinib in gastrointestinal cancers other than GIST.
    Grávalos C, Grande E, Gasent JM.
    Crit Rev Oncol Hematol; 2010 Oct 01; 76(1):36-43. PubMed ID: 20133148
    [Abstract] [Full Text] [Related]

  • 17. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
    George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD.
    Ann Oncol; 2012 Dec 01; 23(12):3180-3187. PubMed ID: 22858558
    [Abstract] [Full Text] [Related]

  • 18. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug 01; 16(90):138-41. PubMed ID: 17724833
    [Abstract] [Full Text] [Related]

  • 19. Sunitinib malate.
    Izzedine H, Buhaescu I, Rixe O, Deray G.
    Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):357-64. PubMed ID: 17136543
    [Abstract] [Full Text] [Related]

  • 20. Sunitinib.
    Rini BI.
    Expert Opin Pharmacother; 2007 Oct 01; 8(14):2359-69. PubMed ID: 17927489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.